ArticleJournal for immunotherapy of cancer2021
Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds.
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Harnessing the potential of γδ T cells through engineering and combination treatment for cancer therapies.Nature communications · 2026Review
- γδ T cells at the interface of innate and adaptive immunity in cancer.Journal for immunotherapy of cancer · 2026Review
- Pre-existing activation states shape functional heterogeneity of human Vγ9Vδ2 T cells.Frontiers in immunology · 2026Article
- Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening.Journal of biological engineering · 2025Review
- MSP-RON signaling in liver pathobiology and as an emerging therapeutic target: a review of the current evidence.Cell communication and signaling : CCS · 2025Review
- Mechanisms and Functions of γδ T Cells in Tumor Cell Recognition.Current oncology (Toronto, Ont.) · 2025Review
- Engineering innate immune cells for cancer immunotherapy.Nature biotechnology · 2025Review
- Review
- Human γδ T cells in the tumor microenvironment: Key insights for advancing cancer immunotherapy.Molecules and cells · 2025Review
- γδT cells, a key subset of T cell for cancer immunotherapy.Frontiers in immunology · 2025Review
- Function and Spatial Organization of Tumor-Invasive Human γδ T Cells-What Do We Know?European journal of immunology · 2025Review
- The recent advancement of TCR-T cell therapies for cancer treatment.Acta biochimica et biophysica Sinica · 2024Review
- Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vγ9Vδ2 T-cell killing.Cellular & molecular immunology · 2024Article
- The present and future of bispecific antibodies for cancer therapy.Nature reviews. Drug discovery · 2024Review
- Gamma delta T cells in cancer therapy: from tumor recognition to novel treatments.Frontiers in medicine · 2024Review
- The therapeutic role of γδT cells in TNBC.Frontiers in immunology · 2024Review
- Therapeutic avenues for γδ T cells in cancer.Journal for immunotherapy of cancer · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.